ClinicalTrials.gg
Not yet recruitingNCT06172686Updated Dec 15, 2023

In-vivo Transmission Model in Semi-immune Adults

A Phase 1 interventional study of Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg). and Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days. in Controlled Human Malaria Infection, Induced Blood Stage Malaria Infection and Malaria Transmission, sponsored by Ifakara Health Institute. Not yet recruiting at 1 site in Tanzania. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by Ifakara Health Institute · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Malaria with a site in Tanzania — 3 open to participants now, 3 under way, none of them phase 3. Malaria · Tanzania.

Planned enrollment
67th of 72
24 · median 616
Started
2024
with 1 other
Phase 1
11 of 79
1 open now
Registered
77th of 79
by date
Lead sponsor
6 of 79
Ifakara Health Institute

Among the 79 studies in Malaria with a site in Tanzania, this one is the 67th largest by planned enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2024, is one of 11 in phase 1, and was the 77th registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

3 of the 79 studies in Malaria with a site in Tanzania are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Tanzania have not opened yet or have stopped. Only those recruiting at a site in Tanzania →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Malaria with a site in Tanzania, or all of them as a file.
02

Study summary

Controlled human malaria infection (CHMI) has revolutionized the development of malaria vaccines. It involves the administration of either known numbers of sporozoites or infected erythrocytes to healthy human volunteers under a controlled environment. The use of highly sensitive molecular malaria diagnostic methods informs treatment decisions before symptom development and allows the characterization of parasite growth dynamics. Sporozoite CHMI has safely been used in six countries in Africa providing a platform to assess the efficacy of candidate malaria vaccines and study the natural immunity to malaria. Blood stage CHMI involves administration of known number of Artemether Lumefantrine sensitive infected erythrocytes in healthy volunteers, and it is a more sensitive model for modelling parasite growths and study the efficacy of blood-stage malaria vaccines. It has been safely used in Australia and Europe but not in Africa. Adaptation of this model by administration of combination of suboptimal and optimal antimalarial drugs lead to increased gametocytaemia, and infection rates in mosquitoes following standard membrane feeding assay. Such adaptation allows the model to be used to study parasite transmission from human to mosquitoes and evaluate transmission blocking malaria interventions.

There is an urgent need to establish an in vivo model for early-stage clinical evaluation of transmission blocking interventions (TBI) in volunteers living in malaria endemic countries. This would allow rapid and cost-effective way to down-select transmission blocking candidate malaria vaccine and gametocidal antimalarial drugs before larger, more complex, and expensive field efficacy studies are conducted. A study done in naïve individual showed 100% success in establishing a malaria infection using 2800 P. falciparum infected RBCs, while a recent study (manuscript in development) has demonstrated success in establishing infection in Tanzanian semi-immune individuals with low malaria exposure using 1000 P. falciparum infected RBCs. We will use 1000 ALU-sensitive 3D7 P. falciparum infected RBCs to establish an in vivo transmission model for studying Transmission blocking interventions and assess the efficiency of two antimalarial drugs regimens (Piperaquine and doxycycline) to induce high levels of gametocytaemia and mosquito infection rates in healthy African adults. We will also investigate the determinants of successful transmission to mosquitoes including underlying immune responses to both asexual and sexual malaria antigens, asexual parasite dynamics and gametocyte burden, sex ratio of male and female gametocytes, and the relationship between gametocyte density and mosquito infection rate

Read the detailed description

Adaptation of blood-stage Controlled Human Malaria Infection for evaluation of transmission blocking malaria interventions in malaria endemic countries.

This will be Phase I Randomized open label trial. It will recruit Healthy male adults aged 18-45 years from low malaria endemic area (Bagamoy0) for three months.

BACKGROUND AND RATIONALE Plasmodium falciparum (Pf) malaria remains a disease of public health significance affecting millions across the globe (1). Scaling up of malaria interventions has reduced the malaria burden in several parts of Africa (2-5), but this has not been consistent everywhere, with some areas reporting sustained or even an increase in the burden of malaria (6, 7). Vaccination is one of the most cost-effective public health interventions (8, 9) and would play a critical role in the elimination efforts. There is a significant development in research to identify promising transmission-blocking malaria vaccines, with several candidate vaccines in the pipeline. To down-select the most promising candidates, antibody tests and functional assays that prevent infection of mosquitoes are normally used (10). It is however unclear how well these assays represent the in vivo transmission-blocking efficacy making it difficult to choose which candidate to develop further (11). Before a transmission blocking vaccine (TBV) can be approved, a randomized trial to evaluate the effect on gametocyte carriage and transmission to mosquitoes or Phase 3 trial to demonstrate vaccine impact on the incidence of infection in the target population are required. Both study designs are large and expensive (11). Alternatively, accelerated approval could be sought through surrogate markers of efficacy that would require either analytical or biological, but not clinical validation. However currently there is no known surrogate markers. Therefore, in vivo transmission blocking model for early-stage clinical evaluation of TBV is needed to rapidly down-select promising candidate vaccines before large field trials are conducted. Although such model has been studied in malaria naïve population, it is important to establish this model in target populations to provide relevant results that considers the genetic background and underlying natural immunity.

03

Conditions studied

  • Controlled Human Malaria Infection
  • Induced Blood Stage Malaria Infection
  • Malaria Transmission
  • Malaria Challenge

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male volunteers aged 18-45 years and in good health.
  • Volunteer has adequate understanding of the procedures of the study and is able and willing (in the investigator's opinion) to comply with all study requirements.
  • Participant is willing and able to give for participation in the trial.
  • Participant with low malaria exposure as determined by anti-schizont ELISA
  • Literacy in Kiswahili.
  • Anti-schizont antibody levels below 50th centile of the most recently available population anti-schizont in Bagamoyo district

Exclusion criteria

Exclusion Criteria:

  • Any history, or evidence at screening, of symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, gastrointestinal, renal, hepatic, neurological, dermatological (e.g. psoriasis, contact dermatitis etc.), allergy, endocrine, malignant, haematological, infectious, immunodeficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results.
  • A heightened risk of cardiovascular disease, as determined by: an estimated ten-year risk of fatal cardiovascular disease of ≥5% at screening, as determined by the Systematic Coronary Risk Evaluation (SCORE); history, or evidence at screening, of clinically significant arrhythmia, prolonged -interval or other clinically relevant abnormalities; or a positive family history of cardiac events in 1st or 2nd degree relatives \<50 years old.
  • (BMI) of \<18 or >30 Kg/m2
  • A medical history of functional asplenia
  • Female volunteers
  • Confirmed parasite positive by PCR a day before challenge i.e., at C-1.
  • Screening tests positive for (HIV), active Virus (HBV), Virus (HCV)
  • Chronic use (>30 days) of i) drugs, ii) antibiotics, iii) or other immune modifying drugs within three months prior to study onset (inhaled and topical and oral antihistamines exempted) or expected use of such during the study period
  • Any recent (within 30 days) or current systemic therapy with an antibiotic or drug with potential antimalarial activity (chloroquine, doxycycline, tetracycline, piperaquine, benzodiazepine, flunarizine, fluoxetine, tetracycline, azithromycin, clindamycin, erythromycin, hydroxychloroquine, etc.) (Allowable time frame for use at the Investigator'sdiscretion).
  • History of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years.
  • Any history of treatment for severe psychiatric disease by a psychiatrist in the past year.
  • History of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset.
  • Previous participation in any malaria product study (allowable time frame for use at the Investigator's discretion)
  • Participation in any other clinical study in the 30 days prior to the start of the study or during the study period.
  • Being an employee or relative of an employee of Ifakara Health Institute.
  • Current participation in another clinical trial or recent participation within 12 weeks of enrolment.
  • Prior receipt of an investigational malaria vaccine.
  • Previous receipt of malaria sporozoites (PfSPZ) or infected RBC as part of the malaria challenge study.
  • Use of immunoglobulins or blood products within 3 months prior to enrolment.
  • Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination.
  • Confirmed parasite positive by qPCR at screening (can be treated and rescreened if time allows)
  • History of epilepsy in the period of five years prior to study onset, even if no longer on medication.
  • Any history of treatment for severe psychiatric disease by a psychiatrist in the past year.
  • History of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset.
  • Known to or (including co-medication) for use of Piperaquine, doxycycline, chloroquine, primaquine, artemether-lumefantrine or history of severe (allergic) reactions to blood transfusion.
  • Any other condition or situation that would, in the opinion of the investigator, place the volunteer at an unacceptable risk of injury or render the volunteer unable to meet the requirements of the protocol
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Arm1

    The first arm will receive Piperaquine tablets , that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).

    Drug: Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg).

  • Experimental
    Arm 2

    The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.

    Drug: Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.

Interventions

  • DrugPiperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg).

    The first arm will receive Piperaquine tablets, that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).

  • DrugDoxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.

    The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.

06

What researchers measure

Primary outcomes

  1. Solicited and unsolicited adverse events

    Frequency of solicited and unsolicited adverse events.

    Time frame: Up to day 98 after blood infection challenge.

  2. Magnitude of Adverse Events

    Magnitude of Adverse Events both solicitated and Unsolicited

    Time frame: Up to day 98 after blood infection challenge.

Secondary outcomes

  1. Rate of Mosquito infections (proportion of infected mosquitoes)

    Rate of Mosquito infections (proportion of infected mosquitoes)

    Time frame: 14, 21 and 28 days after infection challenge

  2. Infection burden (Oocysts density in infected mosquitoes)

    Infection burden (Oocysts density in infected mosquitoes)

    Time frame: 14, 21 and 28 days after infection challenge

  3. Number of volunteers in each study arm that show prevalence of gametocytes as defined by quantitative reverse-transcriptase PCR (qRT-PCR) for CCp4 (female) and pfMGET (male) mRNA with a threshold of 5 gametocytes/mL for positivity.

    Number of volunteers in each study arm that show prevalence of gametocytes as defined by quantitative reverse-transcriptase PCR (qRT-PCR) for CCp4 (female) and pfMGET (male) mRNA with a threshold of 5 gametocytes/mL for positivity.

    Time frame: Up to day 28 after blood infection challenge

  4. Time to peak density gametocytes from the time of challenge as measured by qRT-PCR.

    Time to peak density gametocytes from the time of challenge as measured by qRT-PCR.

    Time frame: Up to day 28 after the blood infection challenge

  5. The area under the curve of gametocyte density versus time for both arms of the study

    The area under the curve of gametocyte density versus time for both arms of the study

    Time frame: Up to day 28 after the blood infection challenge

  6. Gametocyte commitment after the blood infection challenge as estimated by dividing the peak gametocyte by the peak of asexual parasites

    Gametocyte commitment after the blood infection challenge as estimated by dividing the peak gametocyte by the peak of asexual parasites

    Time frame: Up to day 28 after the blood infection challenge

  7. Gametocyte Sex-ratio after blood infection challenge as measured by the proportion of male gametocytes versus female gametocytes.

    Gametocyte Sex-ratio after blood infection challenge as measured by the proportion of male gametocytes versus female gametocytes.

    Time frame: Up to day 28 after the blood infection challenge

07

Study locations

1 site
  • Ifakara Health Institute
    Pwani, Tanzania
08

References and documents

Publications

  • Aregawi MW, Ali AS, Al-mafazy AW, Molteni F, Katikiti S, Warsame M, Njau RJ, Komatsu R, Korenromp E, Hosseini M, Low-Beer D, Bjorkman A, D'Alessandro U, Coosemans M, Otten M. Reductions in malaria and anaemia case and death burden at hospitals following scale-up of malaria control in Zanzibar, 1999-2008. Malar J. 2011 Feb 18;10:46. doi: 10.1186/1475-2875-10-46. PubMed 21332989 ↗
  • Ceesay SJ, Casals-Pascual C, Nwakanma DC, Walther M, Gomez-Escobar N, Fulford AJ, Takem EN, Nogaro S, Bojang KA, Corrah T, Jaye MC, Taal MA, Sonko AA, Conway DJ. Continued decline of malaria in The Gambia with implications for elimination. PLoS One. 2010 Aug 18;5(8):e12242. doi: 10.1371/journal.pone.0012242. PubMed 20805878 ↗
  • Farnert A, Yman V, Homann MV, Wandell G, Mhoja L, Johansson M, Jesaja S, Sandlund J, Tanabe K, Hammar U, Bottai M, Premji ZG, Bjorkman A, Rooth I. Epidemiology of malaria in a village in the Rufiji River Delta, Tanzania: declining transmission over 25 years revealed by different parasitological metrics. Malar J. 2014 Nov 26;13:459. doi: 10.1186/1475-2875-13-459. PubMed 25423887 ↗
  • Okiro EA, Hay SI, Gikandi PW, Sharif SK, Noor AM, Peshu N, Marsh K, Snow RW. The decline in paediatric malaria admissions on the coast of Kenya. Malar J. 2007 Nov 15;6:151. doi: 10.1186/1475-2875-6-151. PubMed 18005422 ↗
  • Assele V, Ndoh GE, Nkoghe D, Fandeur T. No evidence of decline in malaria burden from 2006 to 2013 in a rural Province of Gabon: implications for public health policy. BMC Public Health. 2015 Feb 4;15:81. doi: 10.1186/s12889-015-1456-4. PubMed 25649228 ↗
  • Okiro EA, Bitira D, Mbabazi G, Mpimbaza A, Alegana VA, Talisuna AO, Snow RW. Increasing malaria hospital admissions in Uganda between 1999 and 2009. BMC Med. 2011 Apr 13;9:37. doi: 10.1186/1741-7015-9-37. PubMed 21486498 ↗
  • Holden JD. Benefits and risks of childhood immunisations in developing countries. Br Med J (Clin Res Ed). 1987 May 23;294(6583):1329-31. doi: 10.1136/bmj.294.6583.1329. PubMed 3109642 ↗
  • Robertson RL, Foster SO, Hull HF, Williams PJ. Cost-effectiveness of immunization in The Gambia. J Trop Med Hyg. 1985 Oct;88(5):343-51. PubMed 3939146 ↗
  • Miura K, Swihart BJ, Deng B, Zhou L, Pham TP, Diouf A, Burton T, Fay MP, Long CA. Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay. Vaccine. 2016 Jul 29;34(35):4145-4151. doi: 10.1016/j.vaccine.2016.06.066. Epub 2016 Jun 29. PubMed 27372156 ↗

Individual participant data

Plan to share: Yes — We plan to share the de-identified data on the parasite dynamics and safety of volunteers who participated in the study. This will be done during publication of the study results.

Supporting information: Study protocol

Time frame: within 12 months after study completion

Access criteria: Open access

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Feb 2024, 1 month later.

Of 64 non-industry phase 1 interventional studies under Malaria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's planned 1 month is below that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2023
First posted
Dec 15, 2023
StartEst.
Jan 9, 2024
Primary completionEst.
Feb 13, 2024
CompletionEst.
Jun 30, 2024
Last update
Dec 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06172686
Lead sponsor
Ifakara Health Institute
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Jan 9, 2024 (estimated)
Primary completion
Feb 13, 2024 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Dec 15, 2023

Study contacts

Ally Olotu, MD,Dphil
Contact
aolotu@ihi.or.tz
+255 718 927 104
Enock kessy, BSc,MSc
Contact
ekessy@ihi.or.tz
+255 626 837 898
Ally Olotu, MD,Dphil
principal investigator · Ifakara Health Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion